LBA 92

Negative impact of HLA haplotype DR4DQ8 is stronger than DR3DQ2 in LADA patients: results from a Norwegian and Swedish population

V. Grill 1, I. Hals2, S. Carlsson3, J. Edstorp4, E. Ahlqvist5, E. Sørgjerd6;

1Dept of Clinical and Molecular Medicine, Hässelby, Sweden, 2Dept of Clinical and Molecular Medicine, Trondheim, Norway, 3Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, 4Karolinska Institutet, Solna, Sweden, 5Lund University, Malmö, Sweden, 6HUNT Research Centre, Department Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Levanger, Norway., Levanger, Norway.

Background and aims: Genotypes DR4DQ8 and DR3DQ2 are documented as major risk factors for type 1 diabetes. Corresponding effects on LADA (=Latent Autoimmune Diabetes in the Adult) have been reported, but only in qualitative terms. Here we investigated the frequency and the relative impact of DR4DQ8 and DR3DQ2 using data from two population-based studies.

Materials and methods: We analyzed LADA data from the Norwegian longitudinal Health Study in Trøndelag (HUNT, HUNT 2(1995-97), HUNT3(2006-2008), and HUNT4 (2017-2019)) and the Swedish cross-sectional study ESTRID (Epidemiological Study of Risk factors for LADA and type 2 diabetes). Diagnosis of LADA required positivity of Glutamic Acid Decarboxylase autoantibodies (GADA). For this study levels of GADA were dichotomized (between high and low). HLA haplotypes were categorized as DR3DQ2 (DR3DQ2 positive but DR4DQ8 negative), DR4DQ8 (DR4DQ8 positive but DR3DQ2 negative), combined DR3DQ2 +DR4DQ8, and Other (negative for DR3DQ2 and DR4DQ8).

Results: In the HUNT study population 231 individuals were diagnosed as LADA. Of these, 44 % displayed no risk haplotype, i.e. Other, 20% were DR4DQ8 and 18% DR3DQ2 (single haplotypes). In ESTRID 536 individuals were diagnosed as LADA, 27% displayed Other, 25 % were DR4DQ8 and 18% DR3DQ2. In HUNT a comparison between double haplotypes vs. either one of DR3DQ2 or DR4DQ8 indicated a stronger enhancing effect of doubles vs DR3DQ2 singly than DR4DQ8 singly. For doubles versus DR3DQ2 differences were seen for fasting C-peptide, p<0,006, fasting glucose, p<0.029, insulin treatment, p<0.005 and high GADA p<0,013. For doubles versus DR4DQ8 there were no significant differences except for high GADA, p<0.046. Reciprocally, in ESTRID directly comparing DR4DQ8 haplotype with DR3DQ2 showed higher levels of fasting glucose, median 15,2 vs 11.8 mM, p<0.023 and a tendency for higher HBA1c, 78.0 vs. 60,5 mmol/mol, in DR4DQ8, p< 0.053.

Conclusion: DR4DQ8 and DR3DQ2 are present at equal frequencies in Scandinavian LADA populations. Both haplotypes associate with high levels of GADA, however evidence indicates a stronger negative impact on LADA diabetes by DR4DQ8 than by DR3DQ2. Measurements of each of these haplotypes could give valuable information when assessing the state and prognosis of LADA diabetes.

Disclosure: V. Grill: None.

LBA 93

A simple clinical risk score identifies Chinese patients with severe insulin deficiency diabetes subtypes and adverse outcomes: a prospective cluster analysis

M. Shi 1,2, B. Fan1,2, C. O1, E. Lau1, A. Yang1,2, J. Lui1,2, H. Wu1,2, E. Chow1,2, A. Kong1,2, A. Luk1,2, R. Ma1,2, J. Chan1,2;

1Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China, 2Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.

Background and aims: Clustering analysis identified severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD) with different outcomes. In Asia, diabetes is characterised by young age of diagnosis, low BMI, and low beta-cell function who might benefit from therapies that promote insulin secretion.

Materials and methods: In a consecutive subcohort of Chinese patients diagnosed with T2D enrolled in the Hong Kong Diabetes Register (1995-2019; HKDR) in whom C-peptide and GAD auto-antibodies (GADA) were measured, we performed k-means clustering based on Ahlqvist’s variables (GADA, age of diagnosis, BMI, HbA1c, HOMA2-IR, and HOMA2-B) to identify diabetes subtypes. We compared outcomes including early insulin requirement or its need (A1c>8.5% on two non-insulin glucose-lowering drugs) and analysed the distribution of T2D pathway-specific genetic risk scores (pwGRS) across clusters. We derived a clinical risk score (CRS) using common variables (age of diagnosis, disease duration, HbA1c, fasting plasma glucose, and systolic blood pressure) to predict SIDD. We evaluated its performance in predicting adverse outcomes amongst the remaining patients in the HKDR (1995-2019, n=17,417) without C-peptide or GADA.

Results: Amongst 2,790 insulin-naïve patients with T2D enrolled in 1995-2012 (mean age: 51.5±12.8 years; median disease duration: 3 [IQR: 1-8] years; mean age of diagnosis: 46.1±12.2 years; 48.4% men; median C-peptide: 459.0 [IQR: 167.1-704.3] pmol/L; mean HOMA2-IR: 1.3±1.1; mean HOMA2-B: 47.5±37.2%), we identified five distinct clusters: SAID (4.4%), SIDD (15.1%), SIRD (17.2), MARD (33.3%), and a novel SIDD-like subgroup (young-onset diabetes [YOD]-SIDD; 30.0%) with younger age of diagnosis than SIDD (36.5 vs. 42.3 years). The SAID, SIDD, and YOD-SIDD groups had the lowest HOMA2-B: 38.6%, 23.9%, and 27.0% respectively. During a median follow-up of 15.4 years (43,151 person-years), median time to insulin requirement or its need were: SAID (8.8 years), SIDD (7.2 years), YOD-SIDD (12.6 years), SIRD (10.7 years), and MARD (10.9 years). The YOD-SIDD subgroup was most represented in the top quintile of T2D pwGRS for beta-cell dysfunction (23.3%) and impaired fasting glucose (24.5%). The SIDD group had the highest adjusted incidence of CVD, CKD and all-cause mortality. The ROC of SIDD-CRS for predicting SIDD was 0.98 (95% CI 0.97-0.99) with the optimal cut-off point having an accuracy of 94%. In the validation cohort (mean age: 55.5±12.1 years; median disease duration: 4 [IQR: 1-10] years; mean age of diagnosis: 49.4±12.3 years; 51.8% men) followed up for 8.7 years, the high SIDD-CRS group (n=4,888; 28%) had higher incidence of all events (5.5% vs 3.7%) than the non-SIDD group (n=12,529) with an HR of 1.47 (95% CI 1.39-1.55).

Conclusion: Half of Chinese patients with T2D had severe insulin deficiency associated with adverse outcomes. A simple CRS identified these high-risk individuals who may benefit from early therapies that promote insulin secretion calling for more RCTs in precision therapy.

Supported by: Hong Kong Government Health and Medical Research Grant

Disclosure: M. Shi: None.

LBA 94

Employing Bayesian models to explore and rank different approaches to type 2 diabetes remission: a systematic review and network meta-analysis

Y. Song 1, S. Katsarova2, C. Lawson1, E. Brady1;

1Department of Cardiovascular Sciences, University of Leicester, Leicester, UK, 2Loughborough University, Leicestershire, UK.

Background and aims: It is recognised that Type 2 diabetes (T2D) can be reversed via surgery, lifestyle and pharmacotherapies.

Materials and methods: This systematic review identified both randomised control trials (RCTs) and cohort studies using a pre-determined search strategy applied to three different electronic databases. After removing the duplicates and screening, the data were synthesised using network meta-analysis open access software MetaInsight. T2D remission was defined as HbA1c < 6.5% at least ≥ 3 months without any medication and categorised by duration of follow-up. RCTs and Cohort Studies were analysed separately with Bayesian modelling for ranking. Due to limitations with MetaInsight, random effect modelling and forest plots generated in STATA to determine effect size of studies with single or multiple arms.

Results: Twenty RCTs and 20 cohort studies were identified. RCTs: Interventions were pooled into a total of nine groups to permit data synthesis and produce three network analyses (NWA) by follow-up FU (≤ 1 year, 1-2 years and >2 years). NWA-1: Nine treatments were evaluated across 14 studies with FU ≤ 1 year. Roux-en-Y gastric bypass (RYGB) surgery had a (Surface Under the Cumulative Ranking Curve SUCRA) value of 95.7% for achieving remission vs. Intensive insulin therapy plus incretin analogues with the lowest SUCRA value, at 27.1%. NWA-2: Ten studies with 8 interventions and FU 1-2 years. Sleeve gastrectomy had a SUCRA value of 88.4% vs. Intensive insulin therapy alone or combined with oral drugs with a SUCRA of 25.5%. NWA-3: Eight studies with 6 treatments and FU >2 years (range: 0.5-12 years). Sleeve gastrectomy ranked highest with a SUCRA value of 81.5% vs. Total calorie restriction with/without exercise with the lowest SUCRA (20.5%). Cohort Studies: Interventions were pooled into 7 groups to permit data synthesis and produce two NWAs by FU (≤2 and >2years). NWA-4: Eleven studies (6 interventions, ≤2 FU). Lifestyle management ranked highest with SUCRA 97.3% vs. Adjustable gastric banding (AGB). NWA-5: Four studies (5 interventions, >2years FU). Lifestyle management ranked highest with SUCRA 97.3% vs. AGB. Across both NWA and contrastingly, AGB ranked lowest with SUCRAs of 24.7% and 40.5%, respectively. Random-effects modelling revealed a significant effect in both short- and long-term follow-up groups, albeit with substantial heterogeneity was observed: for studies ≤2 years (n=17), the pooled effect was 0.58 (95% CI: 0.39-0.77; I² = 99.7%), and for studies >2 years (n=6), 0.41 (95% CI: 0.13-0.71; I² = 99.8%), both reaching statistical significance (p < 0.001).

Conclusion: Bariatric surgery revealed the highest effectiveness for diabetes remission across all follow-up periods. However, a high rate of relapse was observed overtime, irrespective of the intervention type-potentially due to the absence of structured remission-maintenance strategies within the interventions. studied.

Supported by: This study is funded by NIHR Leicester BRC

Disclosure: Y. Song: None.

LBA 95

Cardiovascular risk associated with pre-existing and post-transplant diabetes in kidney transplant recipients

H. Kim 1,2, S. Lee1, H. Lee3, J. Lee4, J. Lee4, M. Kim4, E. Kang1,2;

1Internal medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, 2Endocrine research, Seoul, Republic of Korea, 3Yonsei University College of Nursing, Seoul, Republic of Korea, 4Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.

Background and aims: Diabetes mellitus (DM) and cardiovascular disease (CVD) are major public health concerns and remain leading causes of morbidity and mortality following kidney transplantation. Both preexisting diabetes (Pre-DM) and post-transplant diabetes mellitus (PTDM) have been associated with adverse post-transplant outcomes. However, comparative data on their respective contributions to cardiovascular events remain limited. This study aimed to evaluate the impact of Pre-DM and PTDM on the incidence of cardiovascular events in kidney transplant recipients.

Materials and methods: We conducted a retrospective analysis of 1,930 patients who underwent kidney transplantation at a tertiary care center between 1979 and 2020. Patients were stratified into three groups—pre-transplant diabetes mellitus (Pre-DM), post-transplant diabetes mellitus (PTDM), and non-diabetic (Non-DM)—based on the presence and timing of diabetes diagnosis relative to the transplantation date. To assess the association between diabetes status and cardiovascular outcomes, we applied a Cox proportional hazards model. The primary endpoint was the incidence of four-point major adverse cardiovascular events (4P-MACE), comprising myocardial infarction, ischemic or hemorrhagic stroke, hospitalization for unstable angina, and cardiovascular death.

Results: During a median follow-up period of 6.5 years, 4P-MACE occurred in 36 patients (3.1%) in the Non-DM group, 65 patients (14.3%) in the Pre-DM group, and 33 patients (10.7%) in the PTDM group. After adjusting for potential confounders—including age, sex, body mass index, waiting time, ABO incompatibility, number of HLA mismatches, history of cardiovascular disease, donor age, and donor type (living vs. deceased)—Pre-DM was significantly associated with an increased risk of cardiovascular events (hazard ratio [HR] 3.62, 95% confidence interval [CI] 2.29-5.74, p < 0.001). Kaplan-Meier analysis demonstrated that patients with Pre-DM had the highest cumulative incidence of 4P-MACE, followed by those with PTDM, indicating an intermediate risk. Furthermore, all-cause mortality was significantly elevated in the Pre-DM group, whereas no significant difference in mortality was observed in the PTDM group compared to Non-DM patients.

Conclusion: Both pre-transplant diabetes mellitus (Pre-DM) and post-transplant diabetes mellitus (PTDM) were significantly associated with increased cardiovascular risk in kidney transplant recipients. Notably, the risk of cardiovascular events was higher in patients with Pre-DM compared to those with PTDM, highlighting the critical need for more intensive management of cardiovascular risk factors in transplant recipients with pre-existing diabetes to improve long-term outcomes.

Disclosure: H. Kim: None.

LBA 96

Once-weekly insulin efsitora alfa showed consistent time in range and rates of hypoglycaemia throughout the week relative to day of administration in insulin naive adults with type 2 diabetes

T. Martens 1, S. Heller2, A. Bhargava3, L. Ji4, S. Murthy5, V. Patel6, L. Goncalves6, J. Mitra6, A. Murro6, K. Syring6, T. Battelino7;

1International Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA, 2University of Sheffield, Sheffield, UK, 3Iowa Diabetes and Endocrinology Research Center, West Des Moines, IA, USA, 4Peking University People's Hospital, Beijing, China, 5Life Care Hospital & Research Centre, Bangalore, India, 6Eli Lilly and Company, Indianapolis, IN, USA, 7University Medical Center Ljubljana, Ljubljana, Slovenia.

Background and aims: Insulin efsitora alfa (efsitora) is a once-weekly basal insulin in development for the treatment of diabetes. Efsitora demonstrated noninferior improvements in glycated haemoglobin and similar rates of combined clinically significant (level 2 [<3.0 mmol/L; 54 mg/dL]) or severe (level 3) hypoglycaemia compared to insulin degludec in QWINT-2, a Phase 3 study conducted in insulin naïve adults with T2D. This post hoc analysis assessed the efficacy and safety of efsitora throughout the week, relative to the day of administration.

Materials and methods: Periodic blinded continuous glucose monitoring (CGM) sessions were conducted in the QWINT-2 trial. Percent time in range (TIR: 3.9 -10.0 mmol/L [70-180 mg/dL]), time below range (TBR: <3.0 mmol/L [54 mg/dL] or 3.0-3.9 mmol/L [54-70 mg/dL]), and time above range (TAR: 10.0 -13.9 mmol/L [180-250 mg/dL] or >13.9 mmol/L [250 mg/dL]) from the blinded CGM sessions were calculated on the day of efsitora dosing (Day 0) and for 6 days post-administration. CGM parameters from the CGM session in the 4 weeks prior to the primary endpoint (weeks 48-52) are reported here. Patient-reported rates of combined level 2 or 3 hypoglycaemia were also calculated relative to the day of efsitora administration for the 52-week treatment period.

Results: Efsitora treatment demonstrated consistent TIR by-day over the course of the week (figure). TIR over the course of the week was also similar between efsitora and degludec. Efsitora TBR (3.0-3.9 mmol/L [54-70 mg/dL]) was consistently low across the week. Efsitora TBR (<3.0 mmol/L [54 mg/dL]) remained below the international consensus recommendation of <1%. Patient-reported rates of combined level 2 or 3 hypoglycaemia were low and consistent across the week for efsitora and degludec. Efsitora showed rates of 0.47, 0.65, and 0.50, and degludec showed rates of 0.47, 0.30, and 0.37 events per participant per year for Days 0, 3, and 6, respectively.

Conclusion: Use of once weekly efsitora provides steady glycaemic control throughout the week with a consistently low risk of hypoglycaemia, as assessed by blinded CGM in insulin naïve adults with T2D.

Clinical Trial Registration Number: NCT05362058

Disclosure: T. Martens: None.

Author Index

Abadias, M. 836

Abbas, Z. 1068

Abbott, J. 414

Abchee, A. 287

Abdelaal, A. 231

Abdelalim, E. 231, 426, 430

Abdelgader-Khamis, A. 283

Abd El-Hafez, H. A. 1050

Abdel Moneim Elkholy, A. 918

Abdelrahman Ismail, E. 904, 918

Abderrahmani, A. 580

Abdullakutty, J. 1090

Aberer, F. 542

Åberg, S. 335, 336

Aboolian, A. 987

Abou Azar, F. 221

Abouelnasr, S. 904

Abramovich, I. 254

Abu Aqel, Y. 426

Abu Bakar, A. 337

Achenbach, P. 21

Acherman, Y. 590

Acosta, F. M. 650, 655, 732

Acosta Manzano, F. 654

Acosta-Manzano, P. 89

Acree, C. 633, 783

ACTIDIANE study group 779

Adamczewski, H. 343

Adamikova, A. 311

Adams, W. 768

Adamson, K. 822

Adelborg, K. 63

Adeshara, K. 274

Adhikary, P. 1035

Adhinugraha, K. 342, 1029

Admyre, T. 667

Adolfsson, P. 910

Aers, X.-P. 845, 1010

Afanasyev, D. E. 611

Agardh, D. 262

Agarwal, M. 379

Agarwal, S. 691

Aggarwal, R. 4

Agha-Jaffar, R. 850, 1008

Agholme, J. 366

Agocs, G. 751

Aguayo, G. A. 118, 206

Aguilar-Pimentel, J. 659

Aguilera-Venegas, G. 10

Aharon-Hananel, G. 193

Aher, Y. 667

Ah Glele, S. 1113

Ahlqvist, E. 349, 535

Ahlstedt, I. 667

Ahlström, H. 717

Ahluwalia, T. S. 59, 102, 238, 959

Ahmad, B. 383

Ahmad, W. 822

Ahmed, A. 850

Ahmed, I. 426

Ahmed, I. 279

Ahmed, M. 1065

Ahn, J. 552

Ahn, Y.-B. 387

Ahnmark, A. 522

Ahuja, A. 863, 885

Aida, H. 352, 1251

Aiello, E. 302, 441, 460

Aishwarya, A. 417

Aitken, R. 408

Ajjan, R. 953

Ajjan, R. A. 948

Akcan, M. 227

Åkesson, K. 43, 44

Akgün, M. 230

Akhmedullin, R. 328

Akil, A. 279

Akinrimisi, O. I. 590

Akiyama, Y. 352, 1251

Akpınar, Ç. 942

Al-Abdullah, L. 1212

Alam, U. 303, 332, 1083, 1181

Alamdari, A. 699

Al-Ansari, D. E. 674

Alazawi, W. 1249

Albalak, G. 80

Al-Barazenji, T. 430

Albiero, M. 398, 1122

Aldigeri, R. 1152

Aldous, N. 231

Ale, B. M. 1070

Ale, O. A. J. 1070

Alen, R. 466

Aleotti, F. 439

Aleppo, G. 866

Alexandersen, P. 707

Alexiadou, K. 850

Alfano, M. 564

Alfieri, S. 446

Algathafi, L. 726

Alguwaihes, A. M. 926

Al Hageh, C. 287

Alharthi, T. 835

Al-Hasani, H. 551, 649

Alhomsi, A. 646

Ali, G. 426

Alieva, A. 883

Alings, M. 557

Alistair Williams Antibody Facility 93

Alkaabi, L. 308

Alkaabi, S. N. 509

Alkady, H. 835

Alkhefagie, H. G. A. 138

Allali, N. 875

Allegretti, M. 431

Allen, I. 884

Allen, J. 51

Allen, M. 236

Allimuthu, D. 532

Alliod, C. 635

Allison, M. 567

Allison, M. 31

Allouche, R. 817

Allouchery, M. 791

Almaca, J. 114

Almalaraj, I. 23

Almandoz, J. P. 800

Al-mansoori, N. 584

Al-Mashhadi, Z. K. 1229

Almdal, T. 368

Al Mehthel, M. 929

Almehthel, M. 928

Almeida, I. 1169

Almeida, M. 1201

Almirón-Roig, E. 624

Al-Mrabeh, A. 690

Al-Mrabeh, A. H. 383

Alnabulsi, A. 445

Alnabulsi, A. 445

Al Nesf, A. 426

Al-Onaizi, M. 1212

Alonso-Carril, N. 1153

Alqarni, A. 665

Alshannaq, H. 936

Alshareef, M. 835

Alstrup, L. 508, 509

Altaie, N. 796

Altarrah, D. 1212

Altieri, A. 176

Altrogge, J. 1236

Alvarez, A. 926, 930

Alvarez Cuenod, J. 1037

Álvarez Hernández, E. 578

Alvarsson, M. 1140

Alzaid, F. 28, 1212

AlZaim, I. 1138, 1142

Alzebdeh, L. 944

Amabile, G. 434, 627

Aman, A. 1215

Amaro, A. 511, 1031

Ambery, P. 514

Ambrosino, C. 739

Amendolagine, F. I. 398

Amendolagine, F. 1122

Amendolara, R. 1066

Amigo, J. 1108

Amigó, J. 260, 836

Ammi, M. 324

Amoli, M. 271

Amor, A. 1012, 1156

Amor, A. 1153

Amorese, G. 399

Amorim, I. 751

Amouyal, C. 258, 794

Ampudia, F. 899

Amstutz, N. 459

Amuedo, S. 566

An, S. 225

Anagnostakis, F. 246

Anak, S. 485

Anand, S. 1013

Anandhakrishnan, A. 862

Anandhanarayanan, A. 1053

Anastasiou, I. 1182

Anastasiou, I. A. 144

Anazawa, T. 167

Anderko, I. 1055, 1062

Andersen, A. 327

Andersen, B. 741

Andersen, H. 793

Andersen, J. A. 832

Andersen, J. D. 869, 872

Andersen, M. 76

Andersen, M. S. 610

Andersen, M. 11

Andersen, M. K. 549

Andersen, M. 358

Andersen, M. 242

Andersen, O. E. 212

Andersen, S. T. 1228

Andersen, S. B. 869

Andersen, S. 1219

Andersen, T. L. 714

Andersen, U. B. 508, 509

Anderson, S. 124, 371

Andersson, T. 3, 202

Andersson Hall, U. 335, 336, 536

Andjelic, S. 813

Ando, F. 722

Andrade, K. E. 1121

Andrade, R. 1169

Andrén, P. E. 745

Andres, A. 640

Andrews, R. C. 236

Andruszkiewicz, P. 829

Ang, A. L. C. 915

Angelene K M, H. 145

Angeles-Agdeppa, I. 383

Angosto, D. 965

Ansari, D. 14, 1093

Ansari, S. 850

Anson, M. 1181, 332

Anstee, Q. M. 31, 762

Antal, I. 412

Antal, M. 575

Antalová, S. 1118

Antalova, S. 795

Antikainen, A. 238

Anton, N. 1012

Antonetti, L. 750, 1147, 1162

Antoniades, C. 138

Antonio-Villa, N. E. 334

Antonucci, A. 1147

Anyiam, O. 859

Ao, L. 80

Aoki, Y. 667

Aoyama, N. 329

Aoyama, S. 478, 692, 1032

Apau, V. 1198

Apostolopoulos, J. 906

Appel, U. 844

Aprea Perez, J. 451

Aragona, M. 172, 1017

Arany, E. J. 1030

Araszkiewicz, A. 1055, 1062

Arata, N. 344

Ares, J. 378

AReSVi-006 Study Group 1151

Arffman, M. 247

Arhab, A. 1018

Arias-Loste, M. T. 555

Arias Mendoza, N. 961

Arias Sánchez, C. 965

Aringhieri, G. 1069

Arisova, M. 305, 782

Arita, M. 722

Arjunan, D. 1119

Armani, A. 214

Armirola-Ricaurte, C. 102

Armstrong, D. G. 1100

Armstrong, D. 1098

Arnault, G. 118

Arnaut, T. 148

Arni, A. M. 68

Arnold, M. 812

Arnould, T. 744

Arnqvist, H. J. 1241

Aroda, V. 1248

Aroda, V. R. 61

Arola, J. 35

Arora, P. S. 222

Aroucha, P. M. T. 201

Arranz Martín, J. 1114

Arrarte, V. 797

Arribas, C. 640

Arrieta, A. 891

Arrojo e Drigo, R. 449, 633, 783

Arroyo-Díez, F. 905

Arrubla, J. 616

Arshad, M. 933

Artaç, O. B. 942

Aruffo, E. 353

Arulanandam, D. 1064

Asai, K. 170

Asatiani, N. G. 1042

Ascensão, A. 632

Ashcroft, S. 215

Ashford, M. 675

Ashraf, U. 268

Ashworth, A. 276

Asmar, A. 508, 1096

Asokan, A. K. 107

Asong, M. 871

Aspiyan, A. 1063

Assi, E. 431, 434, 627, 967

Asteljoki, J. V. 35

Šťastný, J. 520

Åstrøm Ueland, G. 44

Åsvold, B. O. 349

Atageldiyeva, K. 328

Atawneh, F. 417

Athanasopoulos, S. 1167

Atkins, J. 433

Atlas, G. 220

Attaye, I. 33

Auchus, R. J. 61, 83

Auclair, A. 608

Auddino, S. 302, 441, 460

Augstein, P. 852

Augustin, R. 187

Augustyn, K. 1049

Aureli, A. 735

Aust, D. 451

Austin, G. 807

Automated Insulin Delivery in Diabetes and Advanced Chronic Kidney Disease Study Group 906

Auzanneau, M. 861

Avalos, L. 338

Averna, M. 1126

Avgousti-Varela, I. 558

Avinashi, S. D. 1112

Avolio, A. 198, 454, 788, 1245

Ayis, S. 122, 239, 955, 960, 990

Azab, S. 1013

Azar, A. K. 1160

Aziz, F. 323, 331, 542, 1106

Aziz, M. 1143, 1190

Azmi, S. 332, 1063, 1065

Azriel, S. 260

Azzouz, M. 928

Baba, T. 1079, 1081

Baber, R. 973

Bacchi, S. D. 1067

Bächle, C. 1154

Bachmann, A. 973

Bachmat, E. 943

Bäckhed, F. 802

Backman, H. 347

Backman, J. 747

Badi, R. 430

Bae, S. 226, 669, 730, 765, 819

Baechler, S. 667

Baek, J. 376

Baek, J.-H. 84

Bag, S. 658

Bagger, J. 622

Bagley, B. M. 834

Bagnaresi, F. 1152

Bagri, D. 14, 1093

Bahrami, H. S. Z. 1160, 1174

Bai, M. 1071

Baier, J. M. 1146

Bailey, M. A. 1161

Bailey, T. 61, 83, 184

Bailey, T. S. 182

Baillet-Blanco, L. 865

Bajaj, H. 219

Bajaj, H. S. 73

Bajrami, B. 187

Bakar, M. A. A. 341

Baker, C. J. 1103

Baker, R. L. 437

Bakhti, M. 230, 764

Bakogianni, S. 1231

Balakrishna, Y. 367

Balakrishnan, M. 66

Balan Assalin, H. 25

Balaz, M. 575, 652, 656

Balazova, L. 575, 652, 656

Balboa, D. 165

Baldassarre, M. P. A. 353

Baldi, S. 108, 177

Baldoni, N. 439

Balena, A. 1066

Balkhiyarova, Z. 283, 285, 286, 1227

Ballanti, M. 750

Ballantyne, C. M. 4

Ballarin-Gonzalez, B. 188

Ballaux, D. 54, 845, 1010

Balti, E. V. 92

Banah, A. 665

Banerjee, S. 1060, 1187

Banerjee, S. 1035

Banks, P. 100

Bannon, C. 506, 510

Banu, I. 206, 258

Bao, F. 42, 612

Baptista, F. I. 1031

Baranova, I. 806

Baranowski, B. J. 227

Baratta, R. 903

Barbalata, T. 1250

Barbaro, F. 1066

Barbosa, H. 637

Barbosa, H. C. L. 252

Barbosa, R. 192

Barchetta, I. 564, 583

Bar-Dagan, H. 571

Barella, L. 691

Baretic, M. 1011

Barigou, M. 308, 584

Barison, C. 214

Barkan-Michaeli, R. 571

Barmanray, R. D. 833

Barnard-Kelly, K. 409, 948

Barnes, M. 362

Baron, J. 1171

Baroni, M. G. 583

Barraud, S. 118

Barrett, H. 956

Barrett, T. 20

Barrios, A. 1108

Barros, M. 1169

Barroso, I. 102

Bartl, H. 1075

Bartolomé, A. 424, 425

Barton, S. 1203

Basarir, H. 442

Basco, D. 635

Bashan, N. 515

Bashir, B. 1063

Basile-Álvarez, M. R. 334

Basirian, P. 227

Bassas Letissier, N. 791, 831

Bast, I. 973

Basu, L. 711

Basu Roy, S. 1036

Battini, L. 1017

Baudot, A. 662

Bausch, C. 163, 391

Bautista, K. 406

Bauza, C. 23

Bawlchhim, Z. 625

Bayartsogt, B. 1091

Bayona, A. 1077, 1202

Bazenet, C. 635

Bazila, B. 480, 496

B. Davidson, M. 217

Beadnell, T. 392

Beard, S. 437

Beare, R. 342, 1029

Beato Vibora, P. 260, 905

Beaudry, J. 604, 764

Beaulieu, K. 544

Bebjaková, K. 1118

Bebu, I. 55

Beca, P. 1118

Becerril-Campos, A. 645

Beck, H. 662

Becker, U. 752

Beckmann, A. 752

Bedeir, N. 17

Bee, Y. M. 915

Bee, Y. 356, 860

Bega Guedes, B. 1037

Beghini, M. 525

Beguinot, F. 137, 698

Begum, M. 275

Behan, T. D. 842

Behera, S. 111

Behrendt, M. 522

Beige, J. 973

Beigrezaei, S. 348

Bekka, S. 205

Belcari, T. 1017

Beleza, J. 632

Belgian Diabetes Registry 92

Belgrade, J. 413

Bellido, V. 566

Bellin, M. 401

Bellini, R. 39

Bello-Chavolla, O. Y. 334

Bellucci, A. 227

Bem, R. 311, 900

Benamar, M. 873

Benchimol, A. 1088

Bendtsen, F. 762

Benezech, C. 690

Bengtsson, T. 376

Benhalima, K. 845, 1010

Ben-Haroush Schyr, R. 396, 534

Benhayon, H. 396

Benitz, Y. 937

Ben Nasr, M. 431, 434, 627, 967

Bennet, L. 267

Bennett, A. 864

Bennett, D. 99

Bennett, W. 1165

Bennewitz, K. 518

Ben Signor, C. 258

Bentin, J. M. 707

Benyó, Z. 1004

Ben-Zvi, D. 396, 534

Berendschot, T. 1051, 1222

Berg, T. 314

Bergenstal, R. 55, 182, 218, 953

Bergford, S. 1007

Bergmair, T. 323

Bergman, M. 104

Bergman, M. 384

Bergmann, M. L. 538, 543

Bergström, G. 567

Berini, S. E. 1059

Berk, K. A. C. 775, 785

Berka, B. 262

Berliner, A. 943

Bermeitinger, B. 938, 939

Berna, V. 1066

Bernabé, M. 640

Bernal Mizrachi, E. 254

Bernardi, S. 594

Bernhart, S. H. 759

Berot, A. 118

Berrada, L. 914

Berry, S. 886, 888, 933

Berry, S. A. 825

Berteramo, A. F. 441

Bertolotto, A. 1017

Bertrand, R. 580

Besnard, R. 400

Best, J. D. 1166, 1199

Bevilacqua, C. 602

Beyerlein, A. 343

Bhadada, S. K. 1119

Bhagat, V. 418

Bhangaaley, S. Y. 706

Bhangu, S. 922

Bhargava, R. 161

Bhartia, M. 379

Bhat, S. 146, 147

Bhatt, D. L. 4, 1121

Bhattachar, S. 129

Bhattacharjee, R. 1035, 1036

Bhatti, J. 208

Bhaumik, S. 532

Bi, Y. 245, 1210, 1217, 1252

Bi, Y. 893

Bianchi, C. 1017

Bianchi, M. 39

Biel, J. H. 275

Biertho, L. D. 30

Biessels, G. 248

Biester, T. 1238

Bifano, E. 1106

Bigossi, M. 280

Bigot, C. 767

Bihlet, A. R. 707

Bijkerk, R. 989

Bilande, G. 305

Bilgaiyan, R. 292

Billeter, A. T. 1040

Billingham, E. 685

Billings, L. K. 276, 872

Billmann, F. 1040

Binda, P. 172

Binns-Hall, O. 1107

Binsch, C. 296, 1089, 1188

binti Mohamad, F. 337

Biondi, G. 483

Bird, A. 569

Birk, J. B. 103, 228

Birkeland, K. I. 346

Birkeland, K. 345

Birkenfeld, A. L. 9, 153, 470, 1014

Birkenfeld, A. 319, 325, 384, 1045

Birnbaum, J. 123

Birnbaumer, P. 89

Biscans, A. 667

Bistmuth, E. 258

Biswas, D. 1036

Biver, E. 1186

Bizzotto, R. 302, 614

Bjerg, L. 169, 377, 1228

Björnholm, M. 648

Bjornstad, P. 978

Bjørnvall, C. D. 346

Bjursell, M. 359

Blache, G. 400

Black, J. E. 208

Bladbjerg, E. M. 138

Blair, P. A. 72

Blanc-Bisson, C. 365

Blanco, J. 1156

Bīlande, G. 782

Blasinger, J. 1106

Blauensteiner, N. 861

Blevins, T. 894

Bliznuks, D. 881

Blok, L. C. H. 393

Blom, I. 686

Blond, M. B. 59, 544

Blonde, L. 83

Blondin, D. 216

Blondin, D. P. 697, 701

Blüher, M. 190, 319, 672, 678, 759, 973, 1138

Boardman, F. 20, 409

Boavida, J. M. 1169

Bochukova, E. 1249

Bodis, K. 1089

Bódis, K. B. 1188

Bodis, K. B. 296, 1194

Bódis, K. B. 703

Bodley, G. 635

Boersma, H. E. 1246

Bogdanov, P. 1082

Boggi, U. 399

Bogun, M. M. 17

Bohlmann, D. 709, 752

Boiko, O. 20, 409

Bojsen-Møller, K. N. 138, 858

Bolek, T. 682, 806

Boleková Lanyiová, M. 682

Bolton, T. 204

Bomphrey, L. 1179

Bonaca, M. 821

Bonadonna, R. 28

Bonadonna, R. C. 402, 854, 1152

Bonato, V. 594

Bonde, P. 1096

Bonet, J. 530

Bonet, M. 87

Bonet-Morata, N. 650

Bonfield, G. 72, 265, 270

Bonfim, M. F. 488

Bönhof, G. 56, 1089

Bonifacio, E. 21

Bonnefond, A. 28, 283, 294, 462, 743

Bonvicini, L. 39

Book, Y. 301

Booth, G. L. 247

Borbjerg, M. 60

Borbjerg, M. K. 1051

Bordács, B. 917

Borella, N. D. 854

Borg, M. J. 815

Borg, M. L. 376

Börgeson, E. 645

Borget, I. 875

Borg Inguanez, M. 625

Bornstein, S. 319

Borot, S. 779, 902

Borovoi, L. 1104

Borys, S. 1109

Boscaro, C. 1122

Boschero, A. 637

Boscolo, F. 507

Bose, C. 1060, 1087, 1187

Bosi, E. 409, 411

Bosma, H. 1222

Bosquet, L. 779

Boss, M. 688, 716

Bossi, S. 149

Bosy-Westphal, A. 709

Bottio, T. 1127

Bouabcha, A. 473

Boudra, Z. 527

Bouffard, L. 702

Boughton, C. 51

Bouichrat, N. 440

Bouillet, B. 1113, 1124

Boulet, N. 666

Bound, M. 160, 801

Bourry, J. 794

Bouslama, R. 521

Boutry, R. 743

Bouzid, R. 326

Bowen, B. 738

Bowrey, D. 859

BOX Study Group 93

Boyle, E. 864

Boyle, J. 339, 340

Boyle, J. A. 342, 1029

Boyle, O. 734

Bozkurt, L. 1154

Bracken, R. 57

Brackenridge, A. 909

Brady, E. M. 726

Brændholt Olsen, M. 687

Braendle, M. 1221

Braffett, B. 55

Brahma, M. K. 685

Brand, C. L. 188

Brandt, C. 741

Brandt, D. 851, 899

Brandt, S. 390

Brandtner, E. 939

Brany, D. 806

Bravo-Garcia, A. 158

Breitfeld, J. 973

Brennan, L. 158

Breyner, N. 767

Briand, F. 767

Bridge, K. I. 1139, 1161

Briere, D. A. 738

Briggs, A. 1203

Brighton, C. A. 771

Brinton, E. A. 4

Briones, A. M. 1145

Brito Casillas, Y. 1037

Brito-Casillas, Y. 1034

Britt, J. 1023

Brock, B. 97, 1219

Brock, C. 60, 97

Brødsgaard, R. 57

Broholm, C. 73

Broncucia, H. 410

Brønd, J. C. 543, 549

Brons, C. 11

Brøns, C. 358

Brooke, J. 1198

Brooks, A. 842

Brors, K. 649

Brown, N. 726

Brown, O. I. 1139, 1161

Brown, S. 506

Brownrigg, G. P. 547

Broz, J. 311

Brugnara, L. 550

Bruin, J. 693

Bruin, J. E. 711

Bruin, S. 175, 590

Bruinsma, B. G. 24, 166

Brun, J. 165, 400

Brunasso, A. 530

Brunerova, L. 311

Brunetti, M. 198, 302, 446, 454, 528, 788, 1129, 1245

Brunetto, M. R. 177

Brüning, D. 469

Bruno, A. 1056

Bruno, R. M. 1145

Bruns, A.-F. 1139

Brusgaard, K. 516

Bru-Tari, E. 112, 423

Bruun, J. 327

Bu, L. 300, 617, 630, 755, 998

Buch, A. 605, 890

Buckle, I. 435, 438, 984

Buckley, C. M. 1232

Buckner, J. H. 164

Buettner, M. 518

Bugianesi, E. 31, 555

Bukhari, E. 835

Bukhari, s. 835

Bullock, D. M. 738

Bulum, T. 412

Bunn, R. C. 763

Buompensiere, M. I. 442

Burckhardt, M.-A. 18, 861

Burdet, F. 294

Bureau, I. 365, 875

Burggraaf, B. 623

Burkewitz, K. 633

Burniat, A. 914

Burren, D. 864

Burrinha, T. 662, 715

Burt, C. 20

Burton, M. 516

Burtscher, I. 230

Busch, L. 1188

Busch, R. S. 83

Buse, J. B. 2, 61, 83, 127

Busquets, R. 1108

Butalia, S. 1247

Butaye, F. 255

Butler, T. 66

Buzzetti, R. 1066

Byambasukh, O. 1091

Byrne, E. 1076

Caballero Herrero, M. 965

Cabanilla, C. V. 383

Caccioppoli, C. 1127

Cadiou, J. 602

Cadogan, S. 1006

Cai, H. 62, 828

Cai, L. 173, 1211

Cai, M. 747

Cai, Q. 128

Cai, Z. 370, 586, 588

Caidahl, K. 215

Cajka, T. 795

Calcagni, M. 198

Calcia, M. 863, 885

Calderon, E. 377

Calderoni, I. 1127

Calders, P. 603

Calhoun, P. 207

Cali, A. M. G. 555

Callaghan, B. C. 793

Callaghan, B. 1219

Callebaut, A. 164

Cambria, A. 783

Cameron, F. 220

Camoin, M. 865, 1155

Campanile, M. 1056

Campbell, B. 1023

Campbell, J. 766

Campbell, J. E. 91

Campi, F. 172

Campitelli, M. 739

Campos Campos, M. 628, 1258

Canani, L. 181, 895

Canavan, R. 884

Candido, R. 312, 594

Canducci, F. 434

Cañeque-Rufo, H. 636

Canha, D. 118, 206

Canivell, S. 550

Cannon, S. J. 67

Cantara, S. 493

Cantarero-Cuenca, A. 737

Cantley, J. 232, 414, 481

Canz, M. 1082

Cao, B. 463

Cao, L. 78

Cao, X. 320, 1038

Cao, X. 90

Cao, Y. 565

Capece, U. 198, 454, 788, 1129

Capobianco, M. 971, 1135, 1168

Caporusso, M. 896

Capotosti, F. 635

Cappa Mittestainer, F. 25

Cappellari, R. 398

Cappelli, S. 172

Carafa, A. 1066

Caramelo, B. 511, 671

Carapeto, P. 808

Carcaño, N. 521

Carciero, L. 446, 528, 1245

Cardarelli, F. 499

Cardellini, M. 750, 1147

Cárdenas-Salas, J. 961

Cardoso, P. 131, 194

Carey, E. 884

Cariou, B. 779

Carite, A. 937

Carli, F. 662

Carlsen, H. 43

Carlsson, A. 43

Carlsson, S. 3, 349

Caroline, M. 364

Carpentier, A. 216

Carpentier, A. C. 697, 701, 702

Carr, M. C. 184, 894

Carrai, P. 1230

Carrasquillo, R. O. 894

Carrieri, F. 353

Carrillo Lopez, E. 1114

Carstensen, B. 169, 247

Cart, C. 1023

Carter, S. 185, 186, 828

Caruso, F. 922

Caruso, I. 896

Carvalho, A. 662

Carvalho, M. 637

Carvalho, M. S. 252

Casado, C. 737

Casado Cases, C. 961

Casagrande, V. 750, 1147, 1162

Casbolt, H. 933

Casey, C. 1232

Castaneda, J. 50, 891

Castelli, F. 602

Castelloe, E. 804

Castelo-Branco, M. 671, 1031

Castera, L. 555, 563

Castillo, K. 1012

Castorena, C. 221

Castro, É. 653

Castro Cabezas, M. 557, 623, 1121

Catalano, G. 1230

Cataldo, L. R. 427

Catarig, A. 821

Catassi, C. 411

Catrina, S. 777

Catrina, S.-B. 199, 963

Caturano, A. 524

Caunt, S. 1107

Causarano, A. 441

Cavalera, M. 683

Cavalieri, F. 922

Cavallo, M. G. 564, 583

Cavallo, M. 698

Cavelti-Weder, C. 1221

Cebrian Serrano, A. 764, 766

Cebrian-Serrano, A. 526

Cechova, K. 900

Cejvanovic, V. 870

Cembrowski, M. S. 641

Cen, H. 453

Cerasi, E. 254

Cerna, K. 756

Cesana, G. 439

Cesario, A. 1129

Cezard, G. 204

Cha, B.-S. 553, 992

Cha, H.-J. 999

Chacar, S. 287

Chadha, M. 1201

Chadt, A. 551, 649

Chai, S. 337

Chai, S. M. H. 341

Chai, Z. 968, 982

Chakaroun, R. 759

Chakrapani, A. 667

Chalifa-Caspi, V. 638

Chalkias, M. 558

Chalmers, F. 204

Chalopin, S. 794

Chamnan, P. 789

Champion, A. 548

Chan, J. 263, 279, 290

Chan, J. C. N. 288, 357, 913

Chan, J. 629

Chan, S. H. Y. 475

Chan, W. 860

Chand, A. 685

Chandrashekar, P. 438

Chang, A. M. 894

Chang, E. T. 800

Chang, S. 261

Chao, Y. 1210

Chapeau, D. 110, 429

Chaplin, C. 1249

Charles, M. H. 196

Charrouf, R. 158

Chartier, Y. 258

Chaturvedi, N. 281

Chatziralli, I. 1086

Chatzivasiloglou, V. 1231

Chau, P. H. 155

Chaudhry, M. S. 950

Chauhan, I. S. 532

Chauhan, P. 1201

Cheah, Y. 863, 885

Checa, A. 661

Chen, C. 634, 815

Chen, C. 350

Chen, C.-M. 995

Chen, C. 659

Chen, D. N. 320

Chen, H.-S. 1002

Chen, H. 695, 892, 893

Chen, J.-H. 350

Chen, J. 78

Chen, L. 247, 560, 954, 1001

Chen, L. 185, 186, 872, 873, 927, 970, 976

Chen, L. 1022

Chen, M. 37

Chen, M. 1024

Chen, N. 90

Chen, P. 126

Chen, Q. 572, 912

Chen, S. 432

Chen, S.-P. 527

Chen, S.-Y. 453, 547

Chen, W. 185, 186, 828

Chen, X. 487

Chen, X. 1144, 1197

Chen, X. 1052

Chen, Y. 37, 976

Chen, Y. Y. F. 749

Chen, Y. 969, 980

Chen, Y. 34, 784, 1095

Chen, Y.-W. 713

Cheng, A. 926

Cheng, A. Y. Y. 181, 183, 895

Cheng, B. 157

Cheng, C. 1161

Cheng, C. W. 1139

Cheng, J. 300, 755, 998

Cheng, Q. 695

Cheng, S. 500

Cheng, Y. 325

Cheng, Z. 62, 185, 186, 828

Chera, S. 457

Cherkaoui, I. 422

Cherkaoui, I. 428

Cherrington, A. 631

Cherubini, V. 411

Chevalier, N. 949

Chew, S. 1112

Chhabra, R. 1126

Chia, S. 860

Chiacchiaretta, P. 353

Chien, H.-Y. 1203

Chikalova, I. G. 611

Chilala, C. 204

Child, C. 217

Child, C. J. 183, 184

Chimienti, R. 405

Ching, M. E. A. 693

Ching, M. 711

Chiorino, G. 1056

Chiriacò, M. 105, 108, 159

Chiriaco, M. 177

Chiriacò, M. 5, 529

Chisalita, S. I. 1241

Chitturi, R. 292

Chiying, A. 27

Cho, E.-H. 389

Cho, J. 789

Cho, S. 999, 1224

Cho, Y. 381

Choi, C. 582

Choi, H. 591

Choi, I. 226, 669, 730, 765, 819

Choi, J.-H. 561

Choi, J. 81

Choi, J. C. H. 288

Choi, J. 1148

Choi, M. 992

Choi, S. 282

Choi, S. 225

Choi, S.-E. 225

Choi, W.-I. 552

Chon, H. 226, 730

Chong, K. 995

Choo, J. C. J. 915

Choong, L. L. Y. 757

chouaib, R. 426

Choudhary, P. 52

Choudhary, P. 206, 207, 209, 841, 859, 882, 888, 916, 932, 948, 953

Choudhury Nath, R. 451

Chow, E. W. K. 913

Chow, E. 913

Chow, E. Y. K. 288, 357

Chow, E. 629

Chow, W.-S. 200

Chowdhury, S. 1035, 1036

Chrastecka, N. 442

Christ, A. 642

Christensen, D. H. 793

Christensen, M. 187

Christensen, M. 505

Christensen, M. B. 77, 91

Christie, H. E. 507

Christofides, E. A. 61, 83

Chrysochoou, C. 1167

Chu, L. 247, 1247

Chun, S. 208

Chundru, K. 68

Chung, C.-H. 983

Chung, S. 536

Chung, T. 978

Churilov, L. 978

Chuter, V. 1103

Cianfarani, S. 735

Ciangura, C. 779

Ciccarelli, G. 198, 302, 446, 454, 528, 788, 1129, 1245

Cigarran, S. 514

Cignarelli, A. 483, 896, 1127

Cimbalo, N. 5, 159, 177

Cimini, F. A. 564, 583

Cinek, O. 262

Cinquegrani, G. 1152

Cinti, F. 198, 454, 528, 788, 1129, 1245

Ciobanu, J. I. C. 1250

CIRDIA Study Group 902

Cirelli, M. 564

Citko-Rojewska, A. 934

Citro, F. 1017

Ciudin, A. 647

Claessen, H. 343

Clark, M. 645

Clausen, N. 148

Clausen, T. D. 347

Clemente-Postigo, M. 650, 737

Climent, E. 797

Climent, E. 260

Climente, M. D. M. 1126

Cline, D. L. 641

Clodi, M. 323

CLVR Study Group 23

Cnop, M. 71, 253, 265, 294, 429, 914

Coate, K. 631

Cocita, C. 165

Cockcroft, E. 236

Coester, H.-V. 921

Cohen, N. 906

Cohen, N. D. 864

Cohen, O. 49, 50, 867, 891, 910

Cohen, Y. 193

Cohrs, C. M. 659

Colabufo, C. 1127

Colbert, P. L. 163

Colclough, K. 67, 68, 69

Colin, I. 53, 54

Collado, A. 1140

Collett, C. 1007

Collins, L. 257

Colman, P. G. 171, 833, 1199

Colombini, M. 402, 854

Colvin, L. 99

Comella, F. 1058

Conde, S. 740

Conget, I. 1156

Connery, L. 183, 184

Conradi, L.-C. 1138

Conroy, L. R. 866

Consoli, A. 353

Conway, E. M. 723

Conway, M. W. 685

Conza, D. 698

Cook, K. 417

Cooke, D. 838

Cooper, J. 44

Cooper, M. 922, 968, 982

Coppelli, A. 399

Corcillo, A. 990

Corcoy, R. 87

Cormont, M. 666

Corrêa, L. H. 403

Cortez, A. 671

Coskun, T. 192, 738

Cosson, E. 118, 206

Costagliola, S. 492

Costa-Silva, B. 662, 715

Coughlan, M. T. 435

Couper, J. 220

Courjaret, R. 674

Cousins, R. 65

Crabtree, T. 822

Crabtree, T. S. J. 52, 841

Cramon, P. K. 714

CranioGLP1_FORCE investigators 684

Crawford, K. 128

Crawford, M. 937

Crenier, L. 48, 53, 914

Croce, A. 698

Croos, J. 885

Croos, J. S. 863

Cruciani-Guglielmacci, C. 527, 580

Crysnanto, D. 569

Csanalosi Artigas, M. 621

Csanalosi-Artigas, M. 642

Csermely, A. 402, 854

Cubbon, R. M. 1161

Cuevas, S. 965

Cuevas Del Rosario, E. 962

Cui, Y. 246

Cukierman-Yaffe, T. 248

Cunnane, S. C. 702

Cuthbertson, D. J. 332

Cuthbertson, D. 395

Cutler, M. 449, 633, 783

Cutruzzolà, A. 1237

Cuypers, J. 845, 1010

Cypryk, K. 929

Czupryniak, L. 443, 829

Dabrowska, M. 1242

Dadan, J. 748

D'Addio, F. 431, 434, 627, 967

Dadi, P. 111

Dadson, P. 513

Dagdelen, S. 926

D'Agostino, R. 698

DAFNEplus Study Group 838

Dahl, A. 451

Dahl, D. 894

Dahl, K. 63

Dahlqvist Leinhard, O. 1195

Dahlström, E. 98, 143, 238, 957

Dahm, C. C. 169

Dai, A. 987

Dai, D. 229

Dai, L. 1097

Dai, W. 892

Dai, X. 1249

Dai, Y. 601

Dai, Z. 1209

Daka, B. 567, 802

Dalager-Pedersen, M. 196, 790

Dale, C. E. 281

Dales, J. 268

Dalgaard, L. T. 59, 1099

Dalla Man, C. 507, 530

Dalli, J. 1145

Dalli, L. L. 342, 1029

Dalmas, E. 531

Dalton, M. 146

Daly, C. 734

Damianakou, A. 558

Daminova, L. 977

Damm, P. 347

Dan, K. 482, 694, 1128

Dan, M. 458

Danaher, J. 162

Dandanell, S. 1248

Dang, M. 437

Dangaa, B. 1091

D'Angelo, M. 1058

Dangwal, R. 1101

Daniele, G. 172, 302

Danquah, I. 386

D'Antuono, A. 1152

Danziger, M. M. 396

Da Porto, A. 312

DaR investigators 799

Dardano, A. 172, 302

Darmon, P. 875

Darsalia, V. 40

Das, A. 1090

Das, N. 477, 658, 818

Das, S. 486

Das, T. C. 1036

Dasgupta, B. 420

Dassau, E. 941

Das Sharma, A. 455, 456

Davato, F. 1147

Davatzikos, C. 246

David, A. 286

David, J.-P. 798, 1248

David, M.-P. 1151

David G, A. 1097, 1102

Davidson, H. W. 410

Davidson, M. B. 183

Davidson, M. 218, 219

Davidson, R. K. 455

Davies, J. S. 685

Davies, M. J. 73, 190, 211, 388, 546

Davies, M. 859

D'Avino, A. 411

Davis, M. J. 726

Davis, T. M. E. 141, 1166, 1173, 1193

Davis, W. A. 141, 1173, 1193

Daynes, E. 388

Dąbrowski, M. 1009, 1049

Deambrogio, F. 405

Deanfield, J. E. 2, 127

Deàs-Just, A. 1082

Debacq-Chainiaux, F. 744

De Block, C. 48, 53, 54, 871, 1120

De Bock, G. H. 1246

de Bock, M. 864

de Boer, H. 716

De Boer, I. H. 978

Decarnoncle, M. 744

De Caro, C. 1058

Declèves, A.-E. 744

De Cosmo, S. 312

de Courten, B. 348

DeCourten, B. 162

Deden, L. 688, 689, 716

De Domenico, F. 1132

De Franco, E. 71, 72, 265, 270, 271

DeFronzo, R. A. 61, 83

de Galan, B. 1222

de Galan, B. E. 599, 688, 716, 857, 1184, 1200, 1204, 1205, 1206

Deganutti, G. 1227

De Giovanni, M. 405

Degrace, P. 192

de Haan, B. J. 403

de Haan, J. 1148

de Hert, M. 734

De Hollanda, A. 696

Dei Cas, A. 1152

Dejgaard, T. F. 91

de Jong, J. C. K. 80

De Jong, V. D. 557

de Jonge, W. 175

de Kam, S. 216

de Klerk, J. A. 989

de Koning, E. J. 166

de la Calle, E. 1077

De la Calle de la Villa, E. 1202

de la Fuente, M. G. 424

Delemer, B. 206

Delenne, B. 118, 206

De León Céspedes, M. 962

Delepine, C. 28

Delgadillo Silva, L. 109

Delgado, G. E. 154

Delialis, D. 1167

Delibegovic, M. 445

Delong, T. 419, 437

de Lope Quiñones, S. 1077, 1202

De Lorenzi, V. 499

De Los Angeles Quiroga Pelaez, M. 145, 146

Delplanque, J. 462

Del Prato, S. 172, 971, 1135, 1168

Del Testa, R. 1230

De Luca, C. 253, 294, 499

Del Zoppo, A. 197

Demeester, S. 92

Demetriou, I. 548

De Meulemeester, J. 54, 931

Demeyer, H. 603

Demirkan, A. 283, 285

Demizieux, L. 192

de Mutsert, R. 244, 784

de Nardo, W. 591

Deng, B. 1098

Deng, J. 135, 223

Deng, K. 784

Deng, W. 565

Deng, W. Q. 1013

Deng, W. 1097, 1098, 1100, 1102

Deng, X. 185, 186

Deng, X. 78

Deng, Y. 533

Deng, Y. 299

Deng, Y. 88

Deng, Z. 919

Denholm, R. 204

Dennis, J. 125, 131, 316

Dennis, J. M. 194

Denroche, H. C. 432

De Pauw, P. 92

De Piante, P. 853

de Pouvourville, G. 365

Depypere, H. 603

DeRemigis, A. 931

Derhourhi, M. 462, 743

de Sa, J. R. 201

Desai, D. 1013

De SA Matos, A. 710

Desch, S. 1175

Deschênes, S. 382, 1226

Deshmukh, A. 215

Desiderio, A. 698, 739

De Simone, P. 1230

Desouter, A. K. 92

de Souza, R. J. 1013

Desouza, C. 184

Detournay, B. 365, 875

DEVI collaboration 883

de Villa, F. P. 985

De Vita, F. 1066

Devlin, B. L. 158

DeVries, J. 248, 921

de Wendt, C. 551

Dewhurst-Trigg, R. E. 433

Dewidar, B. 180

de Wit, D. F. 315, 393

de Wit-Verheggen, V. 104

Dey, B. K. 1035, 1036, 1060

Dey, S. 63

de Zoysa, N. 838

Dhaher, N. F. 267

Dhar, U. 383

Dhatariya, K. 1068

Di Angelantonio, E. 204

Dias, A. H. 1146

Dias, R. 409, 1203

Dias, R. P. 20, 257, 442

Diaz Cruz, R. 114

Díaz-Sánchez, J. P. 334

Díaz-Sarmiento, M. M. 1034

Dib, S. A. 201

Di Bella, C. 398

Dibner, C. 673

Di Carlo, P. 353

Di Cianni, G. 312, 971, 1135, 1168

Dickerson, M. 111

Di Dario, A. 1066

Didier, M. 1113

Dieberger, A. 89

Diederich, W. 709, 752

Diedisheim, M. 28, 531

Diem, P. 899

Diep, T. 222

Dietvorst, C. 557

Dietvorst, C. A. W. 775

Di Gioia, L. 896

Di Giorgi, N. 1129

Di Giuseppe, G. 198, 302, 446, 454, 528, 788, 1129, 1245

Dillard, P. 767

DiMarchi, R. 766

Di Marco, M. 1194

Di Molfetta, S. 867, 896, 1182

Dimopoulou, M. 1167

Ding, B. 597

Ding, C. 754

Diniz, M. S. 1033

Dinneen, S. F. 1232

Dinsdale, M. M. 194

Dion, C. 422

Di Paola, R. 1147

Di Piazza, F. 49, 910

Di Pino, A. 725, 903, 1194

Dirinck, E. 1120

Dirksen, C. 858

DiSalvo, L. 833

Distler, M. 451

Divilly, P. 884

Djaballah, K. 928

Djerroud, S. 484

Dlasková, A. 480, 496

Dluzniewski, P. J. 800

Dobesova, D. 656

Dobrzycka, M. 748

Dobson, J. 111

Docherty, N. 676

Dock, L. S. 18

Doi, Y. 1233

Dokshokova, L. 1142

Domazet, S. 119

Domazet, S. L. 6, 549

Dombrovska, N. S. 611

Domínguez, M. H. 1096

Domínguez-Bendala, J. 291

Dominguez-Villar, M. 397

Domján, B. A. 856

Dong, F. 406

Dong, X. 62, 185, 186, 892, 893

Donini, L. M. 750

D'Onofrio, L. 1066

Dons-Jensen, A. 1146

Dorado Avendaño, B. 1202

D'Oria, R. 1127

Doria, A. 1122

Döring, M. 649

Dornhorst, A. 850

dos Santos, C. 449

Dos Santos, M. 836

dos Santos, R. 489

Dotta, F. 302, 441, 460, 493

Dou, Y. 339, 340

Douard, V. 602

Doucette, C. A. 448

Doulatram-Gamgaram, V. 10

Doulatram-Gamgaram, V. 961

Douros, J. 764

Douros, J. 766

Dovc, K. 49

Dover, A. 887

Dover, D. C. 1247

Dowling, J. J. 604

Doyle, R. T. 4

Drab, Z. 1242

Dragutinovic4, I. 757

DREAMBee Study Gestational Diabetes Mellitus Group 344

Drexel, H. 304, 938, 939

Driessen, J. H. M. 46, 1229

Drinkwater, J. J. 141

D. Rosen, E. 1138

Drozd, M. 1161

Drummond, L. 257

Dry, S. E. R. 840

D'Silva, N. 956

Du, C. 435, 438, 984

Du, J. 573, 1136

Du, Q. 422, 428

Du, Q. 930

Dualib, P. M. 201

Duan, J. 221

Duarri, A. 1082

Dubatowka, M. 736

Dubencovs, S. 1150

Dubey, D. 1059

Dubský, M. 1118

Dubsky, M. 900

Ducluzeau, P. 779

Duda-Sobczak, A. 233, 1239

Dudova, J. 639

Dufaitre, L. 206

Dufresne, M. 633

Dugas, M. 568

Duke, D. 941

Dule, S. 564, 583

Duneau, D. 690

Dunn, T. 953

Dunne, J. 409

Dunne, J. L. 442

Dunne, K. I. 641

Dunne, P. J. 1076

Dunø, M. 242

Dupas, B. 1088

Duque do Vale, R. 63

Duraisamy, S. 532

Duraiswamy, M. 780, 1021, 1028, 1043, 1044

Durante, E. 1056

Duran-Vivar, M. 624

Durocher, L. 779

Dürrschmidt, O. 987

Duru, O. 7

Dutta, T. 107

Duvillard, L. 1124

Dvorska, D. 806

Dyson, N. 690

EASA Diabetes Consortium 951, 1235

Eaton, A. 401

Ebert, T. 123, 973

Eckert, A. J. 18

Edd, S. 910

EDENT1FI, 409

EDENT1FI consortium 262

Edgerton, D. 631

Edstorp, J. 349

Edwards, S. 375

Edwards, V. 625

Edwardson, C. 388

Eeg-Olofsson, K. 43, 44, 47, 248, 366

Efthymiou, V. 812

Egan, A. M. 507

Egland, K. 19

Egland, K. A. 392

Egli, D. 422, 428

Ehrenborg, E. 747

Ehrenfeld, S. 820

Ehrmann, D. 116, 390, 899, 1223

Eichenlaub, M. 851

Eichmann, M. 433

Eid, M. 135, 223

Eilerman, B. 83

Einhorn, D. 61, 83

Eisner, K. 227

Eizirik, D. L. 492

Eizirik, D. L. 95, 113, 253, 436, 488

Eizirik, D. 489

Ejskjaer, N. 60, 1047, 1051

Ekbäck, E. 386

Ekelund, S. 843

Ekim, B. 485

Ekinci, E. 616, 906, 978

Ekinci, E. I. 877

Eklöf, N. M. 555

Elbarbary, N. 904, 918

El Bekay, R. 737

Elders, P. J. 996

Elding Larsson, H. 407

El-Dirani, C. 491

Eldor, R. 605, 890

Eleftheriadou, I. 144

Elghattis, Y. 864

El ghormli, L. 55

Elhenawy, Y. 891

Eliasen, A. 73

Eliasson, B. 43, 47, 248, 366

Eliasson Angelstig, S. 963

Eljaszewicz, A. 748

Elksnis, A. 777

Elliott, J. 825, 841, 886, 888, 908

Ellisman, M. H. 449

El-Masri, S. 1067

Elmquist, R. 103

Eloy, R. 165, 400

El-refaiy, E. 1050

ELSA team 20

Elsayed, A. 426

Elsner, P. 304

Elzehery, R. 1050

Ema, F. K. 1163

Emerenziani, G. P. 1237

Emerson, S. S. 127, 710

EMERY, C. 365, 875

Enebish, O. 1091

Eng, P. 1008, 1020

Engelmann, M. D. M. 2, 127

Engl, C. 672, 812

Englert, V. 325

Englund, A. 77, 714

Englund, O. 43

Enkhtugs, K. 1091

Ennis, M. 154

Enomoto, M. 997

Epshteyn, A. 276

Eriksen, A. U. 1186

Eriksen, L. B. 6

Eriksfoss, B. D. 686

Eriksson, J. 717

Eriksson, J. W. 47, 600, 646, 723, 745

Eriksson, L. 814

Eriksson, M. 98, 143

Eriksson, O. 95

Erus, G. 246

Escalada, J. 898

Escobar-Morreale, H. 1202

Escobar-Morreale, H. 1077

Eshel, L. 941

Eskesen, N. 149

Eskola, O. 513

Esposito, I. 180

Esposito, M. 214

Estape, M. 696

Esteghamati, A. 354, 1131

Esteghamati, S. 354, 1131

Estimo Michalani Toledo, M. 1254

Ethier, M. 473

Etzerodt, A. 1138

Eurich, D. T. 1247

Euro, L. 746

Eussen, S. 1222

Eussen, S. J. P. 1145, 1184

Evans, M. L. 841, 948

Evans-Molina, C. 22, 23, 460

Evenou, P. 875

Evirgen, H. 1149

Eyileten, C. 1149

Fabres Machado, U. 1254

Fabris, B. 594

Fadini, G. 1122

Fadulelmula, N. 426

Fadzully, F. 341

Faerch, K. 544

Faergeman, N. 516

Færgeman, N. J. 686

Fagarazzi, C. 1122

Fagherazzi, G. 118, 206

Faillie, J.-L. 791

Fainshtein, C. 571

Falconi, M. 439

Falinska, A. 625

Famulla, S. 921

Fan, B. 263, 288, 290, 357, 629, 913

Fan, K. 625

Fan, S. 1220

Fan, Y. 629, 913

Fang, L. 463

Fang, Y. 415

Fanni, G. 717, 745

Fantoni, G. 614

Fantuzzi, F. 71, 1152

Farmer, B. 631

Farnsworth, N. L. 491

Farrell, K. 55

Fasching, P. 323

Fassan, M. 1056

Fatima, M. 1183

Faucher, P. 684, 794

Fauchier, L. 332

Faurholt-Jepsen, D. 368

Faustini, S. 20

Fauzi, M. 450

Federici, M. 750, 1147, 1162

Fedorova, M. 659

Fedotkina, O. 102

Fedulovs, A. 305, 782, 881, 1150

Fei, J. 952

Feigh, M. 569

Fejfarová, V. 1118

Feldman, E. 1219

Feldman, R. G. 1151

Felipe-Morales, D. 406

Felsinger, R. 803

Femia, F. R. 399, 1230

Fenaux, M. 135, 223

Feng, Q. 80

Feng, R. 58

Feng, X. 37

Fennell, D. 1006

Fenyo, M. I. 1250

Ferdousi, M. 1063

Ferencz, V. 856

Ferguson, G. 783

Fermín-Martínez, C. A. 334

Fernandes, J. 148

Fernandes, M. 264

Fernandez Garcia, J. 961

Fernández-Pérez, L. 1034

Fernelius, S. 923

Féron, F. 1061, 1113

Ferragne, S. 473

Ferrannini, E. 5, 513

Ferrara, A. 338

Ferrari, S. 1186

Ferrat, L. 22

Ferreira, I. 662

Ferreira, S. 1169

Ferretti, E. 441

Ferri, G. 499

Fertleman, M. 397

Festa, A. 304

Festuccia, W. T. L. 653

Fex, M. 427, 465

FIELD Study Investigators 171, 1199

Fignani, D. 441, 460

Figueredo, C. 1012

Finan, B. 764

Findling, J. W. 61

Finer, S. 280

Finertie, H. 7

Finlayson, G. 544

FinnDiane Study Group 143, 274, 957

Finneran, M. 1023

FinnGen, 102

Fintini, D. 735

Finzi, G. 25

Fiorentino, T. V. 177

Fiorenza, M. 242

Fioretto, P. 1122

Fiorina, P. 395, 431, 434, 439, 627, 872, 873, 967

Firneisz, G. 1004

Firth, J. 734

Fisch – Shvalb, N. 941

Fishkin, A. 193

Fissette, L. 1151

Fizazi, A. 744

Flabouris, K. 375

Flacke, F. 952

Flanagan, S. E. 72, 265, 270, 271

Fleetwood, K. 247

Flegka, V. 568, 577, 628, 704

Fleischer, J. 538, 1228

Fleming, T. 518, 628, 1075, 1258

Fletcher, P. 506, 510

Flint, S. A. 158

Flor-Alemany, M. 89

Florese, P. 698

Flotynska, J. 1130

Fløyel, T. 278

Fluhr, G. 897

Flynn, C. R. 633

Fogerholm, M. 676

Folli, F. 25

Fondevila, M. F. 175

Fong, C. H. Y. 200

Fonnesbech-Wulff, C. 77

Fonseca, V. 61, 83

Fontaine, H. 563

Fontalba-Romero, M. 291

Fontana, M. 402

Foo, R. 1016

Forbes, A. 1000

Forbes, J. 984

Forbes, J. M. 435, 438, 956

Ford, B. 690

Forest, A. 30

Forman, J. 77

Forman, J. L. 70

Formoso, G. 353

Forouhi, N. G. 12, 330

Forsander, G. 43

Forschler, F. 479

Forteath, C. D. 1159

Fortin, M. 697

Fosse-Edorth, S. 247

Fotheringham, A. 956, 984

Fotheringham, A. K. 435, 438

Foti, F. 742

Fountoulakis, N. 990

Fourlanos, S. 833, 877, 906

Fourmont, C. 1113

Foussard, N. 865

Fowles, D. J. 950

Fowlkes, J. L. 763

Fox, S. A. 229

Fr1da Study Group 21

Fragante, R. 383

Frampton, R. 75

Francis, F. 1090

Francis, H. 171, 1163, 1199

Francis, J. 223

Francisco Javier, M. 291

Franco, O. H. 348

Franke, K. 649

Franken, R. 33, 590

Frary, E. 189

Frasca, F. 903

Frascerra, S. 105, 108, 159, 177

Fraunberger, P. 938, 939

Freckmann, G. 851

Frederiksen, P. 1174

Fredsted Hagen, B. 687

FreeDM2 Study Group 948

Freeman, J. R. 80

Freitas, B. 229

Frelon, M. 165, 400

French, J. 1179

French, O. 909

Frestis, I. 1231

Freund, A. 1175

Frias, J. 66

Fricke, K. 1194

Friedecky, D. 656

Friedl, N. 21

Friedland, D. 451

Frier, B. M. 298, 951, 1235

Friestad, A. 457

Frimer-Larsen, H. 687

Frimodt-Møller, E. K. 1160

Frisch, F. 701, 702

Fritsche, A. 153, 319, 325, 384, 1014, 1045

Frittitta, L. 903, 1182

Frøbert, O. 372

Froguel, P. 283, 294, 462, 743

Frohnert, B. 406

Frohock, A.-M. 236

Frørup, C. 495

Frost, M. 516

Frost Larsen, L. 189

Fu, A. 871

Fu, D. 1023

Fu, S. 758

Fu, Y. 8, 32

Fu, Y. 893

Fu, Z. 533

Fugui, S. 27

Fuhri Snethlage, C. M. 315, 393

Fuior, E. V. 1250

Fujiki, T. 722

Fujikura, J. 167, 718

Fujita, Y. 504

Fukuda-Doi, M. 1233

Fukui, M. 781, 1196

Fullwood, C. 889

Funck, K. 1137

Funck, K. L. 377

Funck, K. 1146

Furian, L. 398

Fürnsinn, C. 525

Furu, K. 380

Furuhashi, M. 352, 606, 1251

Fusaro, G. 594

Fushimi, Y. 482, 694

Gabarra de Oliveira, A. 25

Gabr, Z. 994

Gabriel, R. 529, 1072

Gabriela, S. 398

Gaenger, S. 939

Gaffuri, A.-L. 165, 400

Gaitan, J. 110

Gajare, D. 14, 1093

Gajewska, K. 382

Galán-García, J. L. 10

Galanopoulou, A. 394

Galasso, V. 483

Galderisi, A. 395

Galeano, F. 259, 903

Gallagher, J. G. 1159

Gallardo Alpizar, N. 640

Galleano, F. 1017

Gallen, G. 863, 885

Gallo, S. 5, 105, 108, 159, 177, 1182

Galluzzi, G. 483

Gan, S. 62

Gangi, S. 218

Gangurde, D. 14, 1093

Ganie, Y. 367

Ganla, M. 772, 773, 1225

Ganss, K. 502

Gao, A. 952

Gao, B. 42, 612

Gao